Table 8.

Validated variants significantly associating with the response of patients to neoadjuvant cytotoxic therapy in the validation phase.

Gene	SNV	Genotypes	Responders 1	Non-Responders 1	p-Value 2	p-Value Adj 4
SLC28A3	rs10868138				0.013	0.266
Solute Carrier Family 28 (Sodium-Coupled Nucleoside Transporter), Member 3—Nucleoside transporter with broad specificity for pyrimidine and purine nucleosides		Common homozygous	102	41
		Rare allele 3	23	1
ATP7A	rs2227291				<0.001	0.004
ATPase Copper Transporting Alpha—Copper transporter		Common homozygous	88	16
		Heterozygous	29	24
		Rare homozygote	9	2
KCNAB1	rs2293194				0.003	0.030
Potassium Voltage-Gated Channel, Shaker-Related Subfamily, Beta Member 1—Pottasium channel		Common homozygous	42	9
		Heterozygous	66	17
		Rare homozygous	19	17
DFFB	rs4376673				0.007	0.017
DNA Fragmentation Factor Subunit Beta—DNA fragmentation factor involved in apoptosis		Common homozygous	115	32
		Rare allele 3	12	11

Footnotes: ¹ numbers of responders (complete or partial remission) or non-responders (stable or progressive disease); ² p-value by the Pearson test; ³ in the absence of rare homozygotes in any of the compared groups, effect of rare allele was evaluated; ⁴ adjusted p-value by the multivariate logistic regression adjusted to disease stage.